CN104628829B - 抗菌肽wy‑21 及其应用 - Google Patents
抗菌肽wy‑21 及其应用 Download PDFInfo
- Publication number
- CN104628829B CN104628829B CN201510065017.XA CN201510065017A CN104628829B CN 104628829 B CN104628829 B CN 104628829B CN 201510065017 A CN201510065017 A CN 201510065017A CN 104628829 B CN104628829 B CN 104628829B
- Authority
- CN
- China
- Prior art keywords
- antibacterial peptide
- lysine
- lys
- antibacterial
- phenylalanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 76
- 241000894006 Bacteria Species 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 10
- 206010061218 Inflammation Diseases 0.000 claims abstract description 8
- 230000003115 biocidal effect Effects 0.000 claims abstract description 8
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- 230000007365 immunoregulation Effects 0.000 claims abstract description 6
- 241000192125 Firmicutes Species 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 208000015181 infectious disease Diseases 0.000 claims abstract description 4
- 239000004475 Arginine Substances 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 108010062796 arginyllysine Proteins 0.000 abstract description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 4
- 239000004472 Lysine Substances 0.000 abstract 2
- KJBQDYDTQCIAFO-ZLELNMGESA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(C)C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O KJBQDYDTQCIAFO-ZLELNMGESA-N 0.000 abstract 1
- KUNFMZSTKSLIEY-GRHHLOCNSA-N (2s)-2-azanyl-3-phenyl-propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=CC=C1 KUNFMZSTKSLIEY-GRHHLOCNSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- -1 glycine lysine glutamic acid phenylalanine lysine Chemical compound 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 description 18
- 241000282898 Sus scrofa Species 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 8
- 206010018910 Haemolysis Diseases 0.000 description 8
- 230000008588 hemolysis Effects 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 108010074109 interleukin-22 Proteins 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 1
- VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 1
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 1
- LLUGJARLJCGLAR-CYDGBPFRSA-N Arg-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N LLUGJARLJCGLAR-CYDGBPFRSA-N 0.000 description 1
- NIUDXSFNLBIWOB-DCAQKATOSA-N Arg-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NIUDXSFNLBIWOB-DCAQKATOSA-N 0.000 description 1
- NPAVRDPEFVKELR-DCAQKATOSA-N Arg-Lys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NPAVRDPEFVKELR-DCAQKATOSA-N 0.000 description 1
- BSGSDLYGGHGMND-IHRRRGAJSA-N Arg-Phe-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N BSGSDLYGGHGMND-IHRRRGAJSA-N 0.000 description 1
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 description 1
- UCHSVZYJKJLPHF-BZSNNMDCSA-N Asp-Phe-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O UCHSVZYJKJLPHF-BZSNNMDCSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010080064 CP-1 peptide Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- MWLYSLMKFXWZPW-ZPFDUUQYSA-N Gln-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O MWLYSLMKFXWZPW-ZPFDUUQYSA-N 0.000 description 1
- YKBUCXNNBYZYAY-MNXVOIDGSA-N Glu-Lys-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YKBUCXNNBYZYAY-MNXVOIDGSA-N 0.000 description 1
- ZIYGTCDTJJCDDP-JYJNAYRXSA-N Glu-Phe-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZIYGTCDTJJCDDP-JYJNAYRXSA-N 0.000 description 1
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 1
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- CYHJCEKUMCNDFG-LAEOZQHASA-N Ile-Gln-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N CYHJCEKUMCNDFG-LAEOZQHASA-N 0.000 description 1
- PDTMWFVVNZYWTR-NHCYSSNCSA-N Ile-Gly-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O PDTMWFVVNZYWTR-NHCYSSNCSA-N 0.000 description 1
- HBJZFCIVFIBNSV-DCAQKATOSA-N Leu-Arg-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O HBJZFCIVFIBNSV-DCAQKATOSA-N 0.000 description 1
- YVKSMSDXKMSIRX-GUBZILKMSA-N Leu-Glu-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YVKSMSDXKMSIRX-GUBZILKMSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- KPYAOIVPJKPIOU-KKUMJFAQSA-N Leu-Lys-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O KPYAOIVPJKPIOU-KKUMJFAQSA-N 0.000 description 1
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 1
- VHNOAIFVYUQOOY-XUXIUFHCSA-N Lys-Arg-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VHNOAIFVYUQOOY-XUXIUFHCSA-N 0.000 description 1
- QIJVAFLRMVBHMU-KKUMJFAQSA-N Lys-Asp-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QIJVAFLRMVBHMU-KKUMJFAQSA-N 0.000 description 1
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 1
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 description 1
- MEQLGHAMAUPOSJ-DCAQKATOSA-N Lys-Ser-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O MEQLGHAMAUPOSJ-DCAQKATOSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- YYRCPTVAPLQRNC-ULQDDVLXSA-N Phe-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC1=CC=CC=C1 YYRCPTVAPLQRNC-ULQDDVLXSA-N 0.000 description 1
- DMEYUTSDVRCWRS-ULQDDVLXSA-N Phe-Lys-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 DMEYUTSDVRCWRS-ULQDDVLXSA-N 0.000 description 1
- PEFJUUYFEGBXFA-BZSNNMDCSA-N Phe-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 PEFJUUYFEGBXFA-BZSNNMDCSA-N 0.000 description 1
- OXKJSGGTHFMGDT-UFYCRDLUSA-N Phe-Phe-Arg Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 OXKJSGGTHFMGDT-UFYCRDLUSA-N 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- WTUJZHKANPDPIN-CIUDSAMLSA-N Ser-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N WTUJZHKANPDPIN-CIUDSAMLSA-N 0.000 description 1
- LRZLZIUXQBIWTB-KATARQTJSA-N Ser-Lys-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRZLZIUXQBIWTB-KATARQTJSA-N 0.000 description 1
- FVFUOQIYDPAIJR-XIRDDKMYSA-N Ser-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CO)N FVFUOQIYDPAIJR-XIRDDKMYSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- 241000751182 Staphylococcus epidermidis ATCC 12228 Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- KLGFILUOTCBNLJ-IHRRRGAJSA-N Tyr-Cys-Arg Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O KLGFILUOTCBNLJ-IHRRRGAJSA-N 0.000 description 1
- XJFXZQKJQGYFMM-GUBZILKMSA-N Val-Cys-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)O)N XJFXZQKJQGYFMM-GUBZILKMSA-N 0.000 description 1
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 1
- 230000005133 heliotropism Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108700022109 ropocamptide Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种抗菌肽WY‑21,其全序列为:缬氨酸‑赖氨酸‑苯丙氨酸‑苯丙氨酸‑精氨酸‑赖氨酸‑亮氨酸‑赖氨酸‑赖氨酸‑丝氨酸‑缬氨酸‑赖氨酸‑谷氨酸‑赖氨酸‑异亮氨酸‑甘氨酸‑赖氨酸‑谷氨酸‑苯丙氨酸‑赖氨酸‑精氨酸。该抗菌肽WY‑21的用途是:制备治疗革兰氏阴性菌或者革兰氏阳性菌感染的广谱抗菌药物;制备发挥免疫调控作用从而降低炎症的药物。
Description
技术领域
本发明属于生物医学技术领域,特别是涉及抗菌肽WY-21及其应用。
背景技术
抗生素滥用造成耐药性细菌的产生,也会造成抗生素在畜产品中残留,带来食品安全问题。由于耐药性问题的严重化,越来越多的抗生素对病原菌丧失了杀伤作用。同时长期使用抗生素会破坏影响肠道的稳态,引起肠道菌群紊乱,从而破坏机体的先天免疫。因此,寻找安全、高效的抗菌药物成为了研究热点。
抗菌肽,又叫抗微生物肽(Antimicrobial Peptides,AMP),是机体先天免疫的重要组成成分,是许多生物体抵抗外来致病菌侵袭的第一道屏障。抗菌肽具有广谱抗菌杀菌活性,且主要通过破坏细菌细胞膜发挥作用,不容易产生耐药性。同时抗菌肽还具有多样的生物学功能:刺激细胞增殖,激活免疫系统,抗病毒,抗肥胖,抗炎症反应。由于其独特作用机制与广泛生物学功能引起了科学界的关注,将其作为设计新型抗菌、抗感染制剂的分子模板。所以说抗菌肽是研发新型高效抗生素替代品的重要突破。
α-螺旋抗菌肽是分布最广泛的抗菌肽,当形成α螺旋结构时通常亲水性残基和疏水性残基分别位于螺旋的两侧,因此呈现结构依赖性的两亲结构。螺旋抗菌肽在水相中一般不具有明显的结构特征,但在富含脂类的细胞膜环境下形成典型的α螺旋结构。此类抗菌肽主要通过破坏细菌细胞膜发挥杀菌作用,导致膜上电解质或其他信号物质的逐级降解等,细菌不易产生耐药性。然而,天然的抗菌肽部分存在免疫原性、抗菌活性低,稳定性差,细胞毒性强,溶血率高等问题限制了其作为抗菌药物的推广应用。因此,寻找分子量小、抗菌活性强、安全性高、稳定性好的抗菌肽是实现抗菌肽部分替代抗生素的关键因素。
发明内容
本发明要解决的技术问题是提供一种安全高效的抗菌肽WY-21及其应用。
为了解决上述技术问题,本发明提供了一种抗菌肽WY-21,其全序列为:缬氨酸-赖氨酸-苯丙氨酸-苯丙氨酸-精氨酸-赖氨酸-亮氨酸-赖氨酸-赖氨酸-丝氨酸-缬氨酸-赖氨酸-谷氨酸-赖氨酸-异亮氨酸-甘氨酸-赖氨酸-谷氨酸-苯丙氨酸-赖氨酸-精氨酸。为序列表NO1所示。
作为本发明的抗菌肽WY-21的改进:所述的抗菌肽WY-21为人工设计合成的α螺旋阳离子多肽,包含21个氨基酸残基,分子量为2624.2Da,等电点为10.79,净电荷为+8。
本发明还同时公开了上述抗菌肽WY-21的用途:制备治疗革兰氏阴性菌或者革兰氏阳性菌感染的广谱抗菌药物。
本发明还同时公开了上述抗菌肽WY-21的用途:制备发挥免疫调控作用从而降低炎症的药物。
备注说明:革兰氏阴性菌包括E.coli ATCC25922、E.coli K 88、E.coli K 12、E.coli EPEC O78:K80、E.coli EPEC O144:K26、E.coli EPEC O44:K74、S.choleraesuisCMCC50020、S.typhimurium CMCC50013、S.enteritidis CMCC50041、P.aeruginosaCMCC27853;革兰氏阳性菌包括S.aureus ATCC25923、S.epidermidis ATCC12228。
本发明的抗菌肽WY-21的使用方法和用量可参照常规抗菌肽(特别是对革兰氏阴性菌或者革兰氏阳性菌感染具有广谱抗菌性能的抗菌肽)的使用方法和用量,例如可参照多肽PG-1和CP-1等。
本发明所设计合成的抗菌肽WY-21为α螺旋阳离子多肽,具有肽链长度较短、稳定性较好、人工合成方便的特点。将抗菌肽WY-21的氨基酸序列经NCBI蛋白数据库搜寻比对,未发现有相同的多肽。抗菌肽WY-21具有净电荷高、抗菌谱广、杀菌作用强等优点,同时具有溶血活性低和细胞毒性小、能发挥免疫调控作用从而降低炎症等特点。
附图说明
下面结合附图对本发明的具体实施方式作进一步详细说明。
图1是不同溶度的抗菌肽WY-21对猪红细胞的溶血率对比图,以上结果为6次独立重复实验平均值。
图2是不同溶度抗菌肽WY-21对猪PMBCs的细胞毒性对比图,LDH表示乳酸脱氢酶,以上结果为6次独立重复实验平均值。
图3是对照组、WY-21组、LPS组、LPS+WY-21组对LPS引起的巨噬细胞炎症的缓解作用对比图。
图4是不同溶度的抗菌肽PG-1对猪红细胞的溶血率对比图。
图5是CP-1对LPS引发的巨噬细胞炎症的缓解作用图。
具体实施方式
下面的实施例进一步说明本发明的实质性内容,但本发明的内容不仅仅局限于此。
实施例1、抗菌肽WY-21的制备
抗菌肽WY-21的制备利用固相化学合成法,根据发明内容中所述的氨基酸序列,用自动多肽合成仪从C端到N端逐一进行合成。通过HPLC反相柱层析脱盐纯化。纯化的抗菌肽WY-21用高效液相色谱HPLC方法鉴定其纯度,纯度高于95%。用基质辅助激光解析电离飞行时间质谱(MALDI-TOF)测定其分子量,与理论分子量基本一致,用自动氨基酸测序仪测定氨基酸序列结构。
人工合成的抗菌肽WY-21包含21个氨基酸残基,分子量为2624.2Da,其全序列为:缬氨酸-赖氨酸-苯丙氨酸-苯丙氨酸-精氨酸-赖氨酸-亮氨酸-赖氨酸-赖氨酸-丝氨酸-缬氨酸-赖氨酸-谷氨酸-赖氨酸-异亮氨酸-甘氨酸-赖氨酸-谷氨酸-苯丙氨酸-赖氨酸-精氨酸。为序列表NO1所示。
抗菌肽WY-21的理化参数如表1所示。
表1、抗菌肽WY-21的理化参数
由表1可知抗菌肽WY-21分子量较小,稳定性较好,正电荷含量高,总亲水性指数小。
实施例2、抗菌肽WY-21的抗菌实验(MIC)
细菌接种于MH琼脂平板,倒置培养至长出单菌落。挑取单菌落接种于3mL MH肉汤培养基中,恒温震荡培养至菌液浑浊。将菌悬液30μL转接至3mL新鲜MH肉汤培养基中,恒温震荡培养至OD600=0.5左右;取菌悬液10μL转接至10mL新鲜MH肉汤培养基中涡旋混匀,此时细菌数需在1×105-5×105CFU/mL,用于MIC的测定。在96孔圆底板中加入90μL菌悬液,再逐一加入10μL相应浓度的二倍梯度稀释的抗菌肽溶液,使终浓度分别为256、128、64、32、16、8、4、2、1、0.5、0.25μg/mL;另外阳性对照为只加100μL菌悬液,阴性对照为100μL MH肉汤培养基;每个处理6个重复;37℃生化培养箱中培养24小时;培养完后观察各孔底部是否有细菌沉淀产生,无肉眼可见细菌沉淀的最小浓度可判定为抗菌物质的MIC。
抗菌肽WY-21的抗菌活性见表2。
表2、抗菌肽WY-21的抗菌活性
表2中,WY-21MIC表示抗菌肽WY-21的最小抑菌浓度,以上结果为6次独立重复实验平均值。
如表2所示,抗菌肽WY-21对受试的革兰氏阳性菌和革兰氏阴性菌具有较强的抗菌活性。
实施例3、抗菌肽WY-21的溶血活性
将肝素抗凝的猪前腔静脉血液和RPMI1640培养基按1:1混匀,利用Ficoll-Paque淋巴细胞分离液离心后,吸取环状乳白色单核细胞层(PMBCs)待用,收集最底层红细胞。用1×PBS溶液清洗红细胞至上清液没有红色。将冲洗好的红细胞和1×PBS按照1:89的体积比混匀制成用于溶血率测定的红细胞工作液。
在96孔板中加入90uL红细胞工作液,加入10uL抗菌肽WY-21的二倍梯度稀释液,使抗菌肽WY-21终浓度为512、256、128、64、32、16、8、4μg/mL,阳性对照使用Triton X-100(终浓度为1%),阴性对照加入10uL 1×PBS,每个处理6个重复。细胞培养箱中培养24h后,1500rpm离心20min。小心吸取上清至新96孔培养板中,用酶标仪测定OD414nm、OD546nm,计算ΔOD值。红细胞溶血率的计算公式为:溶血率(%)=100%*(ΔOD试验-ΔOD阴性对照)/(ΔOD阳性对照-ΔOD阴性对照)。
抗菌肽WY-21的对猪血红细胞的溶血活性结果见图1。
如图1所示,抗菌肽WY-21对猪血红细胞的溶血率低,在512μg/mL浓度时,溶血率低于5%。
实施例4、抗菌肽WY-21的细胞毒性
将分离纯化的PBMCs用培养基RMPI1640稀释至1×106个/mL,按照每孔90uL接种96孔板,同时设背景对照(100μL RMPI1640培养基),低水平对照孔(90μL细胞悬液+10μL PBS)和高水平对照孔(90μL细胞悬液+10μL 20%的TritonX-100)。将96孔板于37℃,5%CO2培养箱中静置培养2h;加入10uL相应浓度的抗菌肽WY-21,使抗菌肽WY-21终浓度分别为512μg/mL、256μg/mL、128μg/mL、64μg/mL、32μg/mL、16μg/mL、8μg/mL,每个处理6个重复。培养箱中培养24h后,向阳性对照孔中加入10μL 20%的TritonX-100,并用移液器吹打混匀,继续培养15min;培养结束后,1500rpm离心10min;离心后自各孔中小心吸取60uL细胞上清转移到透明平底96孔培养板相应孔中;每孔加入稀释好的LDH检测试剂30uL,室温避光震荡培养30min,酶标仪测定OD492nm、OD900nm,计算ΔOD值。
LDH释放率按下面公式计算:LDH释放率(%)=100%*(ΔOD试验-ΔOD阴性对照)/(ΔOD阴性对照-ΔOD阳性对照)。
抗菌肽WY-21对猪外周单核细胞的LDH释放率结果见图2。
如图2所示,在浓度低于256μg/mL时,抗菌肽WY-21猪外周单核细胞的LDH释放率都小于10%,结果表明抗菌肽WY-21的细胞毒性低。
实施例5、抗菌肽WY-21发挥免疫调控作用缓解炎症
猪巨噬细胞(3D4/2细胞系)培养于含10%胎牛血清(FBS)的RPMI-1640完全培养基中,5%CO2浓度的37℃细胞培养箱中培养至约80~90%细胞融合形成单细胞层,细胞计数,铺板。按1×106个/孔接种至6孔板,加入RPMI-1640完全培养基,培养至约80%融合,更换为无血清RPMI-1640培养基(2ml)。用抗菌肽WY-21(20μg/mL)和大肠杆菌LPS(1μg/mL)处理猪巨噬细胞,组别设置如下:对照组、WY-21组、LPS组、LPS+WY-21组(抗菌肽WY-21为20μg/mL,大肠杆菌LPS为1μg/mL)。每组设置六个重复孔,培养24小时后收集细胞。用Trizol提取细胞总RNA,反转录获得cDNA,荧光定量测定IL-6、IL-8、IL-22的相对表达量,内参基因为GAPDH。
抗菌肽WY-21对LPS引起的巨噬细胞炎症的缓解作用结果见图3。
如图3所示,LPS处理巨噬细胞,引起炎症因子IL-6、IL-8、IL-22的表达量显著升高,而抗菌肽WY-21处理可以缓解LPS引发的炎症,降低IL-6、IL-8、IL-22的表达量。
对比例1、通过NCBI蛋白数据库搜寻比对所找到的与本发明的WY-21较类似的多肽LL-37和Cathelicidin-BF15,同时文献查找到的抗菌活性较强的多肽PG-1和CP-1,将上述抗菌肽和抗生素进行如同实施例2~实施例5的检测。
多肽的序列具体如下:
抗菌肽LL-37:Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile GlyLys Glu Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu Arg Asn Leu Val ProArg Thr Glu Ser;
抗菌肽C-BF15:Val Lys Arg Phe Lys Lys Phe Phe Arg Lys Leu Lys Lys SerVal;
抗菌肽PG-1:Arg Gly Gly Arg Leu Cys Tyr Cys Arg Arg Arg Phe Cys ValCys Val Gly Arg;
抗菌肽CP-1:Ser Trp Leu Ser Lys Thr Ala Lys Lys Leu Glu Asn Ser AlaLys Lys Arg Ile Ala Ile Ala Ile Gln Gly Gly Pro Arg。
检测结果如下:如表3所示,LL-37和Cathelicidin-15具有一定的抗菌活性,但是抗菌活性不如抗菌肽WY-21强,PG-1和CP-1的抗菌活性与抗菌肽WY-21相近。然而PG-1的溶血率很高,安全性远低于抗菌肽WY-21(见图4)。同时CP-1对LPS引发的炎症没有缓解作用,发挥免疫调控炎症的效果远不如抗菌肽WY-21(见图5)。
表3、4种抗菌肽的抗菌活性(MIC,μg/ml)
最后,还需要注意的是,以上列举的仅是本发明的若干个具体实施例。显然,本发明不限于以上实施例,还可以有许多变形。本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。
<110> 浙江大学
<120> 抗菌肽WY-21 及其应用
<160> 1
<210> 1
<211> 21
<212> PRT
<213> 人工序列
<220>
<223> 抗菌肽 WY-21
<400> 1
Val Lys Phe Phe Arg Lys Leu Lys Lys Ser Val Lys Glu Lys Ile
1 5 10 15
Gly Lys Glu Phe Lys Arg
20
Claims (4)
1.抗菌肽WY-21,其特征在于:其全序列为:缬氨酸-赖氨酸-苯丙氨酸-苯丙氨酸-精氨酸-赖氨酸-亮氨酸-赖氨酸-赖氨酸-丝氨酸-缬氨酸-赖氨酸-谷氨酸-赖氨酸-异亮氨酸-甘氨酸-赖氨酸-谷氨酸-苯丙氨酸-赖氨酸-精氨酸。
2.根据权利要求1所述的抗菌肽WY-21,其特征在于:所述抗菌肽WY-21为人工设计合成的活性多肽,包含21个氨基酸残基,分子量为2624.2Da,等电点为10.79,净电荷为+8。
3.如权利要求1或2所述的抗菌肽WY-21的用途,其特征在于:制备治疗革兰氏阴性菌或者革兰氏阳性菌感染的广谱抗菌药物。
4.如权利要求1或2所述的抗菌肽WY-21的用途,其特征在于:制备发挥免疫调控作用从而降低炎症的药物。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510065017.XA CN104628829B (zh) | 2015-02-06 | 2015-02-06 | 抗菌肽wy‑21 及其应用 |
EP16746138.3A EP3255059B1 (en) | 2015-02-06 | 2016-02-03 | Antimicrobial peptide wy-21 and use thereof |
PCT/CN2016/073390 WO2016124143A1 (zh) | 2015-02-06 | 2016-02-03 | 抗菌肽wy-21及其应用 |
US15/164,028 US9475843B2 (en) | 2015-02-06 | 2016-05-25 | Antimicrobial peptide WY-21 and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510065017.XA CN104628829B (zh) | 2015-02-06 | 2015-02-06 | 抗菌肽wy‑21 及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104628829A CN104628829A (zh) | 2015-05-20 |
CN104628829B true CN104628829B (zh) | 2017-12-29 |
Family
ID=53208112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510065017.XA Active CN104628829B (zh) | 2015-02-06 | 2015-02-06 | 抗菌肽wy‑21 及其应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9475843B2 (zh) |
EP (1) | EP3255059B1 (zh) |
CN (1) | CN104628829B (zh) |
WO (1) | WO2016124143A1 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104628829B (zh) * | 2015-02-06 | 2017-12-29 | 浙江大学 | 抗菌肽wy‑21 及其应用 |
US11174288B2 (en) | 2016-12-06 | 2021-11-16 | Northeastern University | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria |
CN107496904B (zh) * | 2017-09-21 | 2020-03-17 | 中南大学 | 多肽Lycosin-Ⅰ在制备抗炎和抗弓形虫药物中的应用 |
CN107827966B (zh) * | 2017-10-19 | 2018-11-27 | 浙江大学 | 抗菌肽kr-22及其用途 |
CN107903308B (zh) * | 2017-12-04 | 2019-07-05 | 遵义医学院 | 一种抗菌肽kk26及其应用 |
CN108178780B (zh) * | 2017-12-15 | 2021-05-11 | 东南大学 | 一种短肽修饰单宁酸纳米抗菌剂及其制备方法 |
CN111253474B (zh) * | 2019-10-10 | 2023-07-07 | 应连心 | 一种抗菌肽rg-27及其应用 |
CN110903347A (zh) * | 2019-12-05 | 2020-03-24 | 中国人民解放军陆军军医大学第一附属医院 | 抗菌肽l7及其应用 |
CN111298203B (zh) * | 2020-03-06 | 2022-07-19 | 同济大学 | 一种抗菌肽涂层及其制备方法和应用 |
CN112409457B (zh) * | 2020-11-27 | 2022-04-26 | 常州大学 | 一类抗细菌多肽及其应用 |
CN113461781A (zh) * | 2021-07-14 | 2021-10-01 | 中国药科大学 | 抗菌肽gs18及其用途 |
CN113801214A (zh) * | 2021-08-17 | 2021-12-17 | 贵州师范大学 | 一种大蹄蝠来源抗菌肽ha-cath及其应用 |
TW202317598A (zh) * | 2021-09-01 | 2023-05-01 | 美商艾姆麥克斯治療股份有限公司 | 具有抗微生物活性的胜肽 |
CN114773437B (zh) * | 2022-04-14 | 2024-02-23 | 贵州医科大学 | 具有广谱杀菌活性的抗菌肽及其应用 |
CN115873076B (zh) * | 2022-11-24 | 2024-07-16 | 青岛农业大学 | 一种抗菌肽及其在枯草芽孢杆菌中的表达和应用 |
CN116715732B (zh) * | 2023-07-31 | 2023-10-13 | 中国医学科学院医学生物学研究所 | 一种抗菌肽tc-14及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101215325A (zh) * | 2003-10-17 | 2008-07-09 | 上海高科联合生物技术研发有限公司 | 一组抗菌肽及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100584860C (zh) * | 2007-01-11 | 2010-01-27 | 中国人民解放军第三军医大学第一附属医院 | 一种改建的抗菌肽及其制备方法和应用 |
CN101412753A (zh) * | 2008-09-27 | 2009-04-22 | 中国科学院昆明动物研究所 | 金环蛇抗菌肽cathelicidin-BF及其基因和应用 |
WO2010091294A2 (en) * | 2009-02-05 | 2010-08-12 | The Regents Of The University Of California | New targeted antimicrobial moieties |
CN102294019A (zh) * | 2011-09-07 | 2011-12-28 | 中国科学院昆明动物研究所 | 金环蛇抗菌肽cathelicidin-BF的应用 |
CN103333225A (zh) * | 2013-04-11 | 2013-10-02 | 浙江大学 | 抗菌肽及其制备方法和应用 |
CN104628829B (zh) * | 2015-02-06 | 2017-12-29 | 浙江大学 | 抗菌肽wy‑21 及其应用 |
-
2015
- 2015-02-06 CN CN201510065017.XA patent/CN104628829B/zh active Active
-
2016
- 2016-02-03 WO PCT/CN2016/073390 patent/WO2016124143A1/zh active Application Filing
- 2016-02-03 EP EP16746138.3A patent/EP3255059B1/en not_active Not-in-force
- 2016-05-25 US US15/164,028 patent/US9475843B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101215325A (zh) * | 2003-10-17 | 2008-07-09 | 上海高科联合生物技术研发有限公司 | 一组抗菌肽及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
Expressing antimicrobial peptide cathelicidin-BF in bacillus subtilis using SUMO technology;Luan Chao et al;《Appl Microbiol Biotechnol》;20131013;3651-3658 * |
人源抗菌肽LL-37;杨应华等;《生物化学与生物物理进展》;20031231;847-851 * |
抗菌肽LL-37功能研究综述;喻钢等;《药物分析杂志》;20141231;1890-1896 * |
Also Published As
Publication number | Publication date |
---|---|
US20160257718A1 (en) | 2016-09-08 |
EP3255059A1 (en) | 2017-12-13 |
CN104628829A (zh) | 2015-05-20 |
WO2016124143A1 (zh) | 2016-08-11 |
EP3255059A4 (en) | 2017-12-13 |
US9475843B2 (en) | 2016-10-25 |
EP3255059B1 (en) | 2018-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104628829B (zh) | 抗菌肽wy‑21 及其应用 | |
CN104151415B (zh) | 一种天然抗菌肽Alligatorin4及其应用 | |
CN107652359B (zh) | 抗菌肽kr-32及其用途 | |
CN103554225B (zh) | 一组人工合成的抗菌肽及其应用 | |
CN102924574A (zh) | 抗菌肽lz1和该抗菌肽在制备抗菌药物中的用途 | |
CN107827966B (zh) | 抗菌肽kr-22及其用途 | |
CN107312080A (zh) | 一种来源于gsdmd蛋白的抗菌肽及其应用 | |
CN105237626B (zh) | 一种抗菌肽hjh-3及其应用 | |
CN104177485B (zh) | 一种扬子鳄抗菌肽Alligatorin6及其应用 | |
CN106146643B (zh) | 人α‑防御素5改造体及其应用 | |
CN104163861B (zh) | 一种爬行动物抗菌肽Alligatorin5及其应用 | |
CN102391362B (zh) | 一组动物源性阳离子抗菌肽及其应用 | |
CN113142214A (zh) | 甲基营养型芽孢杆菌wswGH-10的抗菌蛋白的应用及分离纯化方法 | |
CN104478996A (zh) | 一种新型阳离子抗菌肽及其应用 | |
CN107043428A (zh) | 一种α螺旋结构的抗炎杂合抗菌肽及其制备方法和应用 | |
CN115043925B (zh) | 一种改造体抗菌肽oNCM及其应用 | |
CN115010791B (zh) | 一种抗菌肽gw18及其应用 | |
CN114891068B (zh) | 一种抗菌肽gk18及其应用 | |
CN106883288A (zh) | 一种抗菌肽bv21及其用途 | |
Muslim | Improving of antibacterial activity for antibiotics by purified and characterized lectin from Acinetobacter baumannii | |
CN104910265B (zh) | 一种合江棘蛙抗菌肽及其编码序列的基因与应用 | |
CN106432445A (zh) | 一种鹰嘴豆防御素的制备方法及其应用 | |
CN113999297A (zh) | 一种抗菌肽hrNCM及其制备方法与应用 | |
CN104371002B (zh) | 一种非蛋白氨基酸抗菌肽及其应用 | |
CN104119434B (zh) | 黑眶蟾蜍抗菌肽及其基因和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |